Relmada Therapeutics, Inc. (RLMD)

NASDAQ: RLMD · IEX Real-Time Price · USD
19.40
0.76 (4.08%)
May 27, 2022 10:40 AM EDT - Market open
Market Cap581.82M
Revenue (ttm)n/a
Net Income (ttm)-143.28M
Shares Out29.99M
EPS (ttm)-6.99
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume27,066
Open18.77
Previous Close18.64
Day's Range18.01 - 19.40
52-Week Range16.23 - 36.93
Beta0.52
AnalystsBuy
Price Target61.64 (+217.7%)
Earnings DateMay 5, 2022

About RLMD

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

IndustryPharmaceuticals
Founded2004
CEOSergio Traversa
Employees10
Stock ExchangeNASDAQ
Ticker SymbolRLMD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for RLMD stock is "Buy." The 12-month stock price forecast is 61.64, which is an increase of 217.73% from the latest price.

Price Target
$61.64
(217.73% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

CORAL GABLES, Fla. , May 5, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a c...

3 weeks ago - PRNewsWire

Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology

CORAL GABLES, Fla. , April 29, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today...

4 weeks ago - PRNewsWire

Relmada Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022

CORAL GABLES, Fla. , April 28, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced...

4 weeks ago - PRNewsWire

Relmada Therapeutics to Present Data at the Ketamine & Related Compounds International Hybrid Conference 2022

CORAL GABLES, Fla. , April 4, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today ...

1 month ago - PRNewsWire

Here's Why Relmada Therapeutics Shares Are Rising

Relmada Therapeutics Inc (NASDAQ: RLMD) shares are trading higher by 7.2% at $25.01 after the company reported better-than-expected fourth-quarter EPS results. Relmada Therapeutics reported quarterly lo...

2 months ago - Benzinga

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

CORAL GABLES, Fla., March 23, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a...

2 months ago - PRNewsWire

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webca...

CORAL GABLES, Fla., March 16, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced ...

2 months ago - PRNewsWire

Relmada Therapeutics to Participate in Fireside Chats at Two Upcoming Healthcare Events

CORAL GABLES, Fla., March 10, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced ...

2 months ago - PRNewsWire

Relmada Aces REL-1017 Vs Ketamine Study For Abuse Potential

Relmada Therapeutics Inc (NASDAQ: RLMD) has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive disorder or MDD. REL-1017 is a novel NMDA receptor (NMDA...

3 months ago - Benzinga

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential

CORAL GABLES, Fla., Feb. 23, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced t...

3 months ago - PRNewsWire

Relmada Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

CORAL GABLES, Fla., Feb. 10, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced t...

3 months ago - PRNewsWire

Wall Street Analysts See a 231% Upside in Relmada Therapeutics, Inc. (RLMD): Can the Stock Really Move This High?

The mean of analysts' price targets for Relmada Therapeutics, Inc. (RLMD) points to a 231.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem...

4 months ago - Zacks Investment Research

Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry

CORAL GABLES, Fla., Dec. 22, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced t...

5 months ago - PRNewsWire

Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

CORAL GABLES, Fla., Dec. 14, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced t...

5 months ago - PRNewsWire

Relmada Stock Falls After Equity Raise Of $150M To Fund Depression Candidate

Relmada Therapeutics Inc (NASDAQ: RLMD) priced an upsized underwritten public offering of 8.82 million shares at $17.00 per share, with gross proceeds of approximately $150 million.  The offer price rep...

5 months ago - Benzinga

Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

CORAL GABLES, Fla., Dec. 8, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced th...

5 months ago - PRNewsWire

Relmada Therapeutics Announces Proposed Public Offering of Common Stock

CORAL GABLES, Fla., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announc...

5 months ago - GlobeNewsWire

Relmada Therapeutics to Present Data at the 60th Annual Meeting of the American College of Neuropsychopharmacology

CORAL GABLES, Fla., Dec. 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today th...

5 months ago - PRNewsWire

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results

CORAL GABLES, Fla., Nov. 11, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a ...

6 months ago - PRNewsWire

Relmada Therapeutics to Present at the Jefferies London Healthcare Conference

CORAL GABLES, Fla., Nov. 9, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced th...

6 months ago - PRNewsWire

Relmada Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November ...

CORAL GABLES, Fla., Nov. 4, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced th...

6 months ago - PRNewsWire

Relmada Therapeutics to Present Data at the Neuroscience Education Institute Congress

CORAL GABLES, Fla., Oct. 29, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced t...

6 months ago - PRNewsWire

Relmada Therapeutics Provides Regulatory and Development Updates on Ongoing Late-Stage Clinical Program for REL-1017 ...

CORAL GABLES, Fla., Oct. 4, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided reg...

7 months ago - PRNewsWire

Relmada Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

CORAL GABLES, Fla., Sept. 17, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced ...

8 months ago - PRNewsWire

Relmada Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

CORAL GABLES, Fla., Sept. 3, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced t...

8 months ago - PRNewsWire